Cytokines in the treatment of metastatic renal cell carcinoma (MRCC): intravenous interleukin and subcutaneous interferon-alpha versus subcutaneous interleukin and interferon-alpha for good prognosis patients [PERCY DUO]

Trial Profile

Cytokines in the treatment of metastatic renal cell carcinoma (MRCC): intravenous interleukin and subcutaneous interferon-alpha versus subcutaneous interleukin and interferon-alpha for good prognosis patients [PERCY DUO]

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2012

At a glance

  • Drugs Interferon alpha; Interleukin-2; Interleukin-2
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2008 Primary endpoint 'overall survival' has not been met.
    • 15 Sep 2008 Results published in Clinical Cancer Research.
    • 01 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top